LY3537982
LY3537982 is a pharmaceutical drug with 8 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
2
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
Clinical Trials (8)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
A Study of [14C]-LY3537982 in Healthy Participants
A Study of the Effect of Food on LY3537982 in Healthy Participants
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8